UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Building better monoclonal antibody-based therapeutics

Nature reviews. Cancer, 2015-06, Vol.15 (6), p.361-370

Weiner, George J

2015

Volltextzugriff (PDF)

Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge

Cancer research (Chicago, Ill.), 2015-01, Vol.75 (1), p.5-10

2015

Volltextzugriff (PDF)

Cancer Immunotherapy Comes of Age

Journal of clinical oncology, 2011-12, Vol.29 (36), p.4828-4836

2011

Volltextzugriff (PDF)

Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization

The Journal of immunology (1950), 2020-03, Vol.204 (5), p.1386-1394

2020

Volltextzugriff (PDF)

Rituximab: Mechanism of Action

Seminars in hematology, 2010-04, Vol.47 (2), p.115-123

Weiner, George J

2010

Volltextzugriff (PDF)

Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma

Journal of clinical oncology, 2014-11, Vol.32 (31), p.3506-3512

2014

Volltextzugriff (PDF)

Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer

BMC cancer, 2021-07, Vol.21 (1), p.1-14, Article 808

2021

Volltextzugriff (PDF)

Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study

International journal of epidemiology, 2017-12, Vol.46 (6), p.1753-1754i

2017

Volltextzugriff (PDF)

Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity

Journal of hematology and oncology, 2021-12, Vol.14 (1), p.204-204, Article 204

2021

Volltextzugriff (PDF)

Cancer and inflammation: promise for biologic therapy

Journal of immunotherapy (1997), 2010-05, Vol.33 (4), p.335-351

2010

Volltextzugriff (PDF)

Quantification of Receptor Occupancy by Ligand-An Understudied Class of Potential Biomarkers

Cancers, 2020-10, Vol.12 (10), p.2956

2020

Volltextzugriff (PDF)

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement

Blood, 2008-02, Vol.111 (3), p.1456-1463

2008

Volltextzugriff (PDF)

Monoclonal antibody mechanisms of action in cancer

Immunologic research, 2007-11, Vol.39 (1-3), p.271-278

Weiner, George J

2007

Volltextzugriff (PDF)

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

Clinical cancer research, 2008-10, Vol.14 (20), p.6697-6703

2008

Volltextzugriff (PDF)

The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent

Scientific reports, 2021-01, Vol.11 (1), p.1535-11, Article 1535

2021

Volltextzugriff (PDF)

Obesity diminishes response to PD-1-based immunotherapies in renal cancer

Journal for immunotherapy of cancer, 2020-12, Vol.8 (2), p.e000725

2020

Volltextzugriff (PDF)

Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist

Journal for immunotherapy of cancer, 2021-06, Vol.9 (6), p.e002484

2021

Volltextzugriff (PDF)

The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors

Cancers, 2023-10, Vol.15 (20), p.4913

2023

Volltextzugriff (PDF)

Immune checkpoint markers and anti‐CD20‐mediated NK cell activation

Journal of leukocyte biology, 2021-10, Vol.110 (4), p.723-733

2021

Volltextzugriff (PDF)

Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression

Haematologica (Roma), 2018-02, Vol.103 (2), p.297-303

2018

Volltextzugriff (PDF)

CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells

Journal of immunological methods, 2005-09, Vol.304 (1), p.88-99

2005

Volltextzugriff (PDF)

B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation

Blood, 2006-10, Vol.108 (8), p.2712-2719

2006

Volltextzugriff (PDF)

Leveraging oncology collaborative networks and biomedical informatics data resources to rapidly recruit and enroll rural residents into oncology quality of life clinical trials

Journal of clinical and translational science, 2024, Vol.8 (1), p.e135, Article e135

2024

Volltextzugriff (PDF)

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Cancer discovery, 2021-12, Vol.11 (12), p.2998-3007

2021

Volltextzugriff (PDF)

Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma

Clinical cancer research, 2007-10, Vol.13 (20), p.6168-6174

2007

Volltextzugriff (PDF)

1 – 25 von 481

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(444)
Mit Volltextzugriff
(408)

Publikationsform

Sprache

Englisch
(479)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Building better monoclonal antibody-based therapeutics

Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge

Cancer Immunotherapy Comes of Age

Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization

Rituximab: Mechanism of Action

Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma

Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer

Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study

Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity

Cancer and inflammation: promise for biologic therapy

Quantification of Receptor Occupancy by Ligand-An Understudied Class of Potential Biomarkers

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement

Monoclonal antibody mechanisms of action in cancer

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent

Obesity diminishes response to PD-1-based immunotherapies in renal cancer

Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist

The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors

Immune checkpoint markers and anti‐CD20‐mediated NK cell activation

Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression

CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells

B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation

Leveraging oncology collaborative networks and biomedical informatics data resources to rapidly recruit and enroll rural residents into oncology quality of life clinical trials

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma

Suchergebnisse filtern